Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.90 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.90 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.90 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13093036 | 0.91 | SLC6A2 (0.81) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1823096 | 0.91 | SLC6A2 (0.81) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL27410631 | 0.89 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL14167556 | 0.85 | CYP2D6 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL12449963 | 0.85 | CYP2D6 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL25262561 | 0.83 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL25268867 | 0.81 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL2407 | 0.81 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL15335800 | 0.81 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL16446546 | 0.79 | HTR3A (0.81) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | SLC6A2 4827/4885SLC6A4 4678/4885SLC6A3 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.